Intravitreal bevacizumab for pigment epithelial detachments in age-related macular degeneration
详细信息 查看全文
- 作者：Victoria Hamelmann MD ; FEBO (1) (2)
Hans -Martin Helb MD ; FEBO (1) (3)
Carsten H. Meyer MD (1) (4)
Frank G. Holz MD (1)
Nicole Eter MD (1) (5) - 关键词：Age ; related macular degeneration ; AMD ; Avastin ; Bevacizumab ; Fluorescein angiography ; OCT ; Optical coherence tomography ; PED ; Pigment epithelial detachment ; Altersabh盲ngige Makuladegeneration ; AMD ; Avastin ; Bevacizumab ; Fluoreszeinangiographie ; OCT ; Optische Coh盲renztomographie ; PED ; Pigmentepithelabhebung
- 刊名：Spektrum der Augenheilkunde
- 出版年：2013
- 出版时间：August 2013
- 年：2013
- 卷：27
- 期：4
- 页码：184-195
- 全文大小：2937KB
- 参考文献：1. Poliner LS, Olk RJ, Burgess D, Gordon ME. Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology. 1986;93(5):543鈥?1.
2. Meredith TA, Braley RE, Aaberg TM. Natural history of serous detachments of the retinal pigment epithelium. Am J Ophthalmol. 1979;88(4):643鈥?1.
3. Elman MJ, Fine SL, Murphy RP, et al. The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. Ophthalmology. 1986;93(2):224鈥?0.
4. Verhoeff FH, Grossman HP. The pathogenesis of disciform degeneration of the macula. Trans Am Ophthalmol Soc. 1937;35:262鈥?4.
5. Murphy RP, Yeo JH, Green WR, Patz A. Dehiscences of the pigment epithelium. Trans Am Ophthalmol Soc. 1985;83:63鈥?1.
6. Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. Retina. 1985(2005);25(5 Suppl):615鈥?7.
7. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch鈥檚 membrane. A histochemical and morphologic study. Ophthalmology. 1990;97(2):171鈥?.
8. Bird AC, Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc U K. 1986;105(Pt 6):674鈥?2.
9. Gass JD. Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization. Retina. 1984(2003);23(6 Suppl):205鈥?0. CrossRef
10. The Moorfields Macular Study Group. Retinal pigment epithelial detachments in the elderly. A controlled trial of argon laser photocoagulation. Br J Ophthalmol. 1982;66(1):1鈥?6.
11. Pece A, Isola V, Vadala M, Calori G. Photodynamic therapy with verteporfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration. Retina. 2007;27(3):342鈥?. CrossRef
12. Axer-Siegel R, Ehrlich R, Avisar I, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging. 2006;37(6):455鈥?1.
13. Lommatzsch AP, Heimes B, Gutfleisch M, et al. Treatment of vascularized serous pigment epithelium detachment in AMD鈥攐bservations after changing the intravitreal agent due to lack of response. Klin Monbl Augenheilkd. 2008;225(10):874鈥?. CrossRef
14. Ruppenstein M, Ach T, Hoh A, Dithmar S. Effect of intravitreal bevacizumab on pigment epithelial detachment in occult choroidal neovascularization. Ophthalmologe. 2010;107(9):827鈥?0. CrossRef
15. Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond). 2009;23(12):2163鈥?. CrossRef
16. Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina. 2010;30(9):1420鈥?. CrossRef
17. Ritter M, Bolz M, Sacu S, et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye (Lond). 2010;24(6):962鈥?. CrossRef
18. Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clin Ophthalmol. 2010;4:369鈥?4. CrossRef
19. Ladas ID, Kotsolis AI, Papakostas TD, et al. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina. 2007;27(7):891鈥?. CrossRef
20. Shima C, Gomi F, Sawa M, et al. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(7):899鈥?06. CrossRef
21. el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):779鈥?4. CrossRef
22. Hajouli N, Hirsh A, Quintyn JC. Triple therapy for the treatment of choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. J Fr Ophtalmol. 2010;33(7):487鈥?2. CrossRef
23. Frimpong-Boateng A, Varde MA, Rufer F, et al. Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD. Ophthalmologe. 2008;105(7):661鈥?. CrossRef
24. Subramanyam A, Phatak S, Chudgar D. Large retinal pigment epithelium rip following serial intravitreal injection of avastin in a large fibrovascular pigment epithelial detachment. Indian J Ophthalmol. 2007;55(6):483鈥?.
25. Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol. 2007;17(4):674鈥?.
26. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina. 2007;27(4):445鈥?0. CrossRef
27. Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina. 2009;30(2):203鈥?1. CrossRef
28. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol. 1985;69(6):397鈥?03. CrossRef
29. Pauleikhoff D, Loffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):533鈥?. CrossRef
30. Schuman JS, Fujimoto JG, Puliafito CA. Optical coherence tomography of ocular diseases. Slack Incorporated; 2004/5.
31. Eter N, Bindewald A, Roth F, Holz FG. OCT in age-related macular degeneration. Findings, usage in clinical routine, and assessment of treatment outcome. Ophthalmologe. 2004;101(8):794鈥?03.
32. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375鈥?13. CrossRef
33. Gass JDM. Stereoscopic atlas of macular disease: diagnosis and management. St. Louis:Mosby; 1997.
34. Gass JD. Retinal pigment epithelial rip during krypton red laser photocoagulation. Am J Ophthalmol. 1984;98(6):700鈥?.
35. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment鈥揟AP and VIP report No. 2. Arch Ophthalmol. 2003;121(9):1253鈥?8. CrossRef
36. Schaal KB, Engler C, Schutt F, et al. Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD. Ophthalmologe. 2008;105(6):538鈥?3. CrossRef
37. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(10):1868鈥?5. CrossRef
38. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006;19(3):361鈥?2.
39. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245(1):68鈥?3. CrossRef
40. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627鈥?7. CrossRef
41. Cohen SY, Korobelnik JF, Tadayoni R, et al. [Monitoring anti-VEGF drugs for treatment of exudative AMD]. J Fr Ophtalmol. 2007;30(4):330鈥?. CrossRef
42. Helb HM, Issa PC, Fleckenstein M, et al. Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol. 2010;88(8):842鈥?. CrossRef
43. Meyer CH, Helb HM, Eter N. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series]. Ophthalmologe. 2008;105(2):125鈥?8,140鈥?2. CrossRef
44. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363鈥?2.e365. CrossRef
45. Smretschnig E, Krebs I, Moussa S, et al. Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. Graefes Arch Clin Exp Ophthalmol. 2010;248(12):1693鈥?. CrossRef
46. Mylonas G, Ahlers C, Malamos P, et al. Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol. 2009;93(11):1453鈥?0. CrossRef
47. Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol. 2009;29(5):349鈥?7. CrossRef
48. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol. 2008;146(1):91鈥?. CrossRef
49. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27(4):439鈥?4. CrossRef
50. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3115鈥?0. CrossRef
51. Moutray T, Alarbi M, Mahon G, et al. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularization. Br J Ophthalmol. 2008;92(3):361鈥?. CrossRef
52. Ting TD, M Oh, Cox TA, et al. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol. 2002;120(6):731鈥?. CrossRef
53. Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina. 2005;25(6):691鈥?. CrossRef
54. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355(14):1432鈥?4.
55. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419鈥?1. CrossRef
56. Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age related macular degeneration. Br J Ophthalmol. 2006;90(9):1207鈥?. CrossRef
57. Pece A, Introini U, Bottoni F, Brancato R. Acute retinal pigment epithelial tear after photodynamic therapy. Retina. 2001;21(6):661鈥?. CrossRef
58. Michels S, Aue A, Simader C, et al. Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone. Am J Ophthalmol. 2006;141(2):396鈥?. CrossRef
59. Yeo JH, Marcus S, Murphy RP. Retinal pigment epithelial tears. Patterns and prognosis. Ophthalmology. 1988;95(1):8鈥?3.
60. Dhalla MS, Blinder KJ, Tewari A, et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol. 2006;141(4):752鈥?. CrossRef
61. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(4):623.e1.
62. Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol. 1981;65(6):417鈥?2. CrossRef
63. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina. 2007;27(5):535鈥?0. CrossRef
64. Weinberger AW, Thiel M, Mohammadi B, et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol. 2007;144(2):294鈥?. CrossRef
65. Kook D, Wolf A, Neubauer AS, et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress. Ophthalmologe. 2008;105(2):158鈥?4. CrossRef - 作者单位：Victoria Hamelmann MD, FEBO (1) (2)
Hans -Martin Helb MD,FEBO (1) (3)
Carsten H. Meyer MD (1) (4)
Frank G. Holz MD (1)
Nicole Eter MD (1) (5)
1. Dept. of Ophthalmology, University of Bonn, Bonn, Germany
2. Augentagesklinik MVZ ADTC D眉sseldorf, D眉sseldorf, Germany
3. Augenzentrum Westpfalz, Kaiserslautern, Germany
4. Dept. of Ophthalmology, Klinik Pallas, Olten, Switzerland
5. Dept. of Ophthalmology, University of M眉nster, Domagkstr. 15, 48149, M眉nster, Germany
文摘